Document is current

Article History

Received: 24 September 2024

Accepted: 24 March 2025

First Online: 22 May 2025

Declarations

:

: PB samples from HDs or leukoreduction system chambers (LRSC) from plate-apheresis were collected with written consent following the Declaration of Helsinki and with approval from the Institutional Review Board of LMU Munich (23–0283). The collection of ovarian cancer tissue for biobanking and generation of organoids has been approved by the Ethics Commission of LMU University (17–0471), and written consent of each patient has been obtained.

: Not applicable.

: K-P.H., M.S., and N.C.F. are inventors of a patent application regarding the SIRPα‑antibody fusion proteins. M.S. has received industry research support from Amgen, Gilead, Miltenyi Biotec, Morphosys, Roche, and Seattle Genetics, and has served as a consultant/advisor to Amgen, BMS, Celgene, Gilead, Pfizer, Novartis, and Roche. She sits on the advisory boards of Amgen, Celgene, Gilead, Janssen, Novartis, Pfizer, and Seattle Genetics, and serves on the speakers' bureau at Amgen, Celgene, Gilead, Janssen, and Pfizer. F.T.: grants and personal fees from AbbVie, AstraZeneca, Eisai, GSK, ImmunoGen, MSD, Roche, and SAGA diagnostics S.M.: Research funding, advisory board, honorary or travel expenses: AbbVie, AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Hubro, Immunogen, Medac, MSD, Novartis, Nykode, Olympus, PharmaMar, Pfizer, Roche, Seagen, Sensor Kinesis, Teva. M.K.: inventor of the European Patent for ovarian cancer organoid culture. B.C.: Honoraria from AstraZeneca. A.L., A.R., B.H., E.P., K.W., B.T., A.H-C.; A.S., L.R., L.Wi., L.Wy., C.W., D.M., declare no relevant conflicts of interest.